Department of Vascular Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands; MIRA Institute of Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.
Department of Vascular Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands.
J Vasc Surg. 2019 Aug;70(2):615-628.e7. doi: 10.1016/j.jvs.2018.11.022. Epub 2019 Apr 5.
In this study, we systematically reviewed late open conversions after failed endovascular aneurysm repair (EVAR), assessed the methodologic quality of the included studies, and performed a meta-analysis on the 30-day mortality rates for urgent and elective late conversions.
Electronic databases were systematically searched for studies published up to June 2018 that focused on late open conversion of failed EVAR (ie, >30 days after the initial EVAR), reported the primary outcome of 30-day mortality rate, and distinguished the 30-day mortality rate between urgent and elective late conversions. Two independent reviewers assessed the methodologic quality of the included studies with the Methodological Index for Non-Randomized Studies. Data on baseline demographics, indication for conversion, surgical approach, and early and late mortality rates were recorded. Reported data correspond to the average or range of the means reported in the individual studies. A random-effects model was used to pool 30-day mortality rates for urgent and elective late conversion.
There were 27 retrospective studies with a total of 791 patients available for analysis, with 617 elective and 174 urgent late conversions. The methodologic quality was mostly poor (median, 6; interquartile range, 5-7). The mean time from primary EVAR to conversion was 35.1 months (95% confidence interval [CI], 30.4-39.8 months). The most commonly explanted endografts were Excluder (W. L. Gore & Associates, Flagstaff, Ariz) in 16.2%, Talent (Medtronic, Minneapolis, Minn) in 14.5%, and AneuRx (Medtronic) in 13.7%. Nineteen other types of endografts were used in 43.3%; the type of endograft was not reported in 12.3%. A transperitoneal approach was used in a mean 74.0% of conversions (95% CI, 70.9%-77.0%), and complete endograft explantation was performed in 478 (60.4%) patients (95% CI, 57.0%-63.8%). The complication rate was 36.7% (95% CI, 27.0%-46.4%). Temporary or permanent hemodialysis after conversion was required in 3.9% of patients (95% CI, 2.6%-5.2%). The pooled estimate for the 30-day mortality rate was 2.8% (95% CI, 1.5%-4.0%; P = .726) for elective late conversions and 28.1% (95% CI, 18.9%-37.3%; P < .001) for urgent late conversions.
Type I endoleak and rupture are the most common indications for, respectively, elective and urgent conversions. A 10 times higher 30-day mortality rate was observed for patients treated with late open conversion in an urgent vs elective setting. The 30-day mortality rate of elective late open conversions is almost comparable to that of primary elective open abdominal aortic aneurysm repair procedures. For the interpretation of the outcomes of the review, however, the methodologic quality of the available literature should be considered.
本研究系统回顾了血管内修复(EVAR)失败后的晚期开放转换,评估了纳入研究的方法学质量,并对紧急和择期晚期转换的 30 天死亡率进行了荟萃分析。
系统检索了截至 2018 年 6 月发表的研究,重点是 EVAR 失败后的晚期开放转换(即初次 EVAR 后>30 天),报告了 30 天死亡率的主要结局,并区分了紧急和择期晚期转换的 30 天死亡率。两名独立的审查员使用非随机研究方法学指数评估纳入研究的方法学质量。记录了基线人口统计学、转换指征、手术方法以及早期和晚期死亡率的数据。报告的数据对应于个别研究中报告的平均值或范围。使用随机效应模型对紧急和择期晚期转换的 30 天死亡率进行汇总。
共有 27 项回顾性研究,共有 791 例患者可供分析,其中 617 例为择期和 174 例为紧急晚期转换。方法学质量大多较差(中位数 6 分;四分位距 5-7 分)。从初次 EVAR 到转换的平均时间为 35.1 个月(95%置信区间 30.4-39.8 个月)。最常被取出的内支架为 Excluder(戈尔公司,亚利桑那州弗拉格斯塔夫)占 16.2%,Talent(美敦力公司,明尼苏达州明尼阿波利斯)占 14.5%,AneuRx(美敦力)占 13.7%。其他 19 种内支架占 43.3%;12.3%的研究未报告内支架类型。74.0%的转换采用经腹入路(95%置信区间 70.9%-77.0%),478 例(60.4%)患者行完全内支架取出(95%置信区间 57.0%-63.8%)。并发症发生率为 36.7%(95%置信区间 27.0%-46.4%)。3.9%的患者在转换后需要临时或永久性血液透析(95%置信区间 2.6%-5.2%)。择期晚期转换的 30 天死亡率的汇总估计值为 2.8%(95%置信区间 1.5%-4.0%;P=.726),紧急晚期转换的 30 天死亡率为 28.1%(95%置信区间 18.9%-37.3%;P<.001)。
I 型内漏和破裂分别是择期和紧急转换的最常见指征。与择期相比,紧急情况下进行晚期开放转换的患者 30 天死亡率高 10 倍。择期晚期开放转换的 30 天死亡率与初次择期开放性腹主动脉瘤修复术几乎相当。但是,对于审查结果的解释,应考虑到现有文献的方法学质量。